Published in J Urol on June 01, 2003
Comparison of laparoscopic and mini incision open donor nephrectomy: single blind, randomised controlled clinical trial. BMJ (2006) 2.32
Morbidity of 200 consecutive cases of hand-assisted laparoscopic living donor nephrectomies: a single-center experience. J Transplant (2012) 1.01
Prevention of poor psychosocial outcomes in living organ donors: from description to theory-driven intervention development and initial feasibility testing. Prog Transplant (2012) 0.96
Robotic-assisted laparoscopic donor nephrectomy: decreasing length of stay. Ochsner J (2015) 0.90
"First, do no harm": monitoring outcomes during the transition from open to laparoscopic live donor nephrectomy in a Canadian centre. Can J Surg (2008) 0.88
Maximizing the donor pool: use of right kidneys and kidneys with multiple arteries for live donor transplantation. Surg Endosc (2009) 0.85
The mini-incision donor nephrectomy is best suited for Indian patients undergoing live donor nephrectomy: against the motion. Indian J Urol (2010) 0.84
Pain management in laparoscopic donor nephrectomy: a review. Pain Res Treat (2012) 0.83
Analgesic Effect of Preoperative Pentazocine for Laparoscopic Cholecystectomy. Cureus (2016) 0.82
Laparoscopic live donor nephrectomy for right kidneys: Experience in a German community hospital. Surg Endosc (2008) 0.80
Renal transplantation today. Langenbecks Arch Surg (2008) 0.80
A double-blind randomized controlled trial of continuous intravenous Ketorolac vs placebo for adjuvant pain control after renal surgery. Mayo Clin Proc (2012) 0.79
Quality of life following living donor nephrectomy comparing classical flank incision and anterior vertical mini-incision. World J Urol (2005) 0.78
Comparison of Acute and Chronic Pain after Open Nephrectomy versus Laparoscopic Nephrectomy: A Prospective Clinical Trial. Medicine (Baltimore) (2016) 0.76
A comparison between intravenous lidocaine and ketamine on acute and chronic pain after open nephrectomy: A prospective, double-blind, randomized, placebo-controlled study. Saudi J Anaesth (2017) 0.75
Quality of life following laparoscopic living-donor nephrectomy. JSLS (2013) 0.75
Transplantation: focus on kidney, liver and islet cells. Can J Surg (2004) 0.75
Comparative Study of the Effect of Intravenous Paracetamol and Tramadol in Relieving of Postoperative Pain after General Anesthesia in Nephrectomy Patients. Anesth Essays Res (2017) 0.75
Laparoscopy, dorsal lumbotomy and flank incision live donor nephrectomy: comparison of donor outcomes. Can Urol Assoc J (2013) 0.75
Mini-incision living donors nephrectomy using anterior muscle-splitting approach with hybrid technique. Int J Organ Transplant Med (2010) 0.75
Optimal surgical strategies in living kidney donation. Can Urol Assoc J (2016) 0.75
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA (2011) 7.61
Autonomic nerve development contributes to prostate cancer progression. Science (2013) 6.11
Marital status and survival in patients with cancer. J Clin Oncol (2013) 5.82
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst (2009) 4.87
Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol (2011) 4.60
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
A framework for the identification of men at increased risk for prostate cancer. J Urol (2009) 3.07
Flexible ureteroscopy and laser lithotripsy for multiple unilateral intrarenal stones. Eur Urol (2008) 2.97
Use, costs and comparative effectiveness of robotic assisted, laparoscopic and open urological surgery. J Urol (2012) 2.94
Hospital volume, utilization, costs and outcomes of robot-assisted laparoscopic radical prostatectomy. J Urol (2012) 2.79
Comparative effectiveness of perineal versus retropubic and minimally invasive radical prostatectomy. J Urol (2010) 2.77
Economic costs of overactive bladder in the United States. Urology (2009) 2.68
The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst (2008) 2.46
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol (2013) 2.46
Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology (2010) 2.45
Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol (2013) 2.39
Influence of surgeon and hospital volume on radical prostatectomy costs. J Urol (2012) 2.37
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
Radical retropubic prostatectomy and robotic-assisted laparoscopic prostatectomy: likelihood of positive surgical margin(s). Urology (2010) 2.31
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev (2006) 2.28
Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis. Urology (2011) 2.24
Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. J Urol (2009) 2.23
Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database. Urology (2009) 2.23
Robot-assisted versus open radical prostatectomy: the differential effect of regionalization, procedure volume and operative approach. J Urol (2012) 2.22
Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation. BJU Int (2013) 2.12
Stepwise approach for nerve sparing without countertraction during robot-assisted radical prostatectomy: technique and outcomes. Eur Urol (2011) 2.09
Association between exercise and primary incidence of prostate cancer: does race matter? Cancer (2013) 2.07
High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06
Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol (2012) 2.05
Comparison of outpatient narcotic prescribing patterns after minimally invasive versus retropubic and perineal radical prostatectomy. J Urol (2011) 2.05
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology (2013) 2.04
Obesity and prostate cancer: weighing the evidence. Eur Urol (2012) 2.01
Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer (2006) 1.97
The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol (2009) 1.97
Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer (2007) 1.96
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer. J Urol (2010) 1.94
The role of genetic markers in the management of prostate cancer. Eur Urol (2012) 1.88
Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol (2012) 1.86
Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer (2011) 1.85
The correlation between metabolic syndrome and prostatic diseases. Eur Urol (2011) 1.83
Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. Urology (2010) 1.83
Use of haemostatic agents and glues during laparoscopic partial nephrectomy: a multi-institutional survey from the United States and Europe of 1347 cases. Eur Urol (2007) 1.82
Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Eur Urol (2012) 1.81
Flexible ureteroscopy and laser lithotripsy for single intrarenal stones 2 cm or greater--is this the new frontier? J Urol (2008) 1.80
Factors associated with the adoption of minimally invasive radical prostatectomy in the United States. J Urol (2012) 1.78
Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database. Prostate (2012) 1.76
Temporal national trends of minimally invasive and retropubic radical prostatectomy outcomes from 2003 to 2007: results from the 100% Medicare sample. Eur Urol (2011) 1.76
Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol (2009) 1.75
Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol (2014) 1.74
Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. BJU Int (2013) 1.73
Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. Rev Urol (2002) 1.71
Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer (2013) 1.66
The relationship between nutrition and prostate cancer: is more always better? Eur Urol (2012) 1.66
Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol (2012) 1.64
Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev (2012) 1.63
Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol (2007) 1.63
Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes. Urology (2013) 1.63
Timing of curative treatment for prostate cancer: a systematic review. Eur Urol (2013) 1.63
Understanding variation in primary prostate cancer treatment within the Veterans Health Administration. Urology (2012) 1.62
Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer (2010) 1.59
Athermal division and selective suture ligation of the dorsal vein complex during robot-assisted laparoscopic radical prostatectomy: description of technique and outcomes. Eur Urol (2010) 1.58
Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int (2014) 1.58
Trends in the care of radical prostatectomy in the United States from 2003 to 2006. BJU Int (2010) 1.57
Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int (2011) 1.54
Effect of ketorolac on renal function after donor nephrectomy. Urology (2002) 1.52
The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer. Cancer (2014) 1.51
The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy. World J Urol (2012) 1.51
Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res (2006) 1.50
Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology (2006) 1.50
Native nephrectomy for renal cell carcinoma in transplant recipients. Transplantation (2011) 1.48
A systematic review of the volume-outcome relationship for radical prostatectomy. Eur Urol (2013) 1.48
Technical refinement and learning curve for attenuating neurapraxia during robotic-assisted radical prostatectomy to improve sexual function. Eur Urol (2012) 1.45
The effect of dietary sodium and fructose intake on urine and serum parameters of stone formation in a pediatric mouse model: a pilot study. J Urol (2013) 1.44
Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. Int J Radiat Oncol Biol Phys (2010) 1.44
Greater percent-free testosterone is associated with high-grade prostate cancer in men undergoing prostate biopsy. Urology (2012) 1.43
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2011) 1.42
Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer (2014) 1.41
Obesity and prostate cancer: importance of race and stage of disease. J Urol (2007) 1.41
2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA (2012) 1.41
Association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy. Int J Urol (2012) 1.40
Use of heparin and protamine sulfate during laparoscopic donor nephrectomy. Transplantation (2002) 1.39
Testosterone replacement therapy in men with prostate cancer: a time-varying analysis. J Sex Med (2014) 1.39
Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the SEARCH database. Urology (2012) 1.39
Randomized controlled trial of barbed polyglyconate versus polyglactin suture for robot-assisted laparoscopic prostatectomy anastomosis: technique and outcomes. Eur Urol (2010) 1.38
Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol (2011) 1.36
Ureteral tumor thrombus from renal cell carcinoma extending into bladder. Urol Oncol (2007) 1.36
Rising PSA in nonmetastatic prostate cancer. Oncology (Williston Park) (2007) 1.35